ObGyns Respond to High Cost of Makena
March 14, 2011
Washington, DC -- The American College of Obstetricians and Gynecologists (The College), along with the American Academy of Pediatrics and the Society for Maternal-Fetal Medicine, is urging Ther-Rx Corporation to reconsider its pricing of Makena™. Makena is the first FDA-approved medication to help prevent preterm birth in certain high-risk pregnant women. The College argues that the extremely high cost of Makena™ will hinder access and affordability to this treatment for both insured and uninsured patients.
To read the full letter, go to 20110311GoedekeLtr.pdf
The American College of Obstetricians and Gynecologists (The College), a 501(c)(3) organization, is the nation's leading group of physicians providing health care for women. As a private, voluntary, nonprofit membership organization of approximately 55,000 members, The College strongly advocates for quality health care for women, maintains the highest standards of clinical practice and continuing education of its members, promotes patient education, and increases awareness among its members and the public of the changing issues facing women's health care. The American Congress of Obstetricians and Gynecologists (ACOG), a 501(c)(6) organization, is its companion organization. www.acog.org
Follow us on Twitter 
Check us out on YouTube